Public consultation on the review of guidance on expiry of compounded parenteral medicines – Pharmacy Board of Australia *Guidelines on compounding of medicines*

1 February 2016

Responses to consultation questions

Please provide your feedback as a Word document (or equivalent)[1] to pharmacyconsultation@ahpra.gov.au by close of business on Wednesday 30 March 2016.

Stakeholder Details

If you wish to include background information about your organisation please provide this as a separate word document (not PDF).

Organisation details
Organisation name: Cabrini Hospital Pharmacy Department **Contact name: Duncan Marsh** **E-mail address:** [redacted]

[1] You are welcome to supply a PDF file of your feedback in addition to the word (or equivalent) file, however we request that you do supply a text or word file. As part of an effort to meet international website accessibility guidelines, AHPRA and National Boards are striving to publish documents in accessible formats (such as word), in addition to PDFs. More information about this is available at www.ahpra.gov.au/About-AHPRA/Accessibility.aspx.

Your responses to consultation questions on the draft proposed guidance

1. Has the proposed guidance been expressed clearly?	Yes it is set out clearly.
2. Does the revised guidance adequately address the concerns raised by stakeholders, that the published (postponed) guidance would inhibit or impact patient access to compounded parenteral medicines?	Yes it does adequately address these concerns.
3. Does the revised guidance support patient safety when supplying compounded parenteral (sterile injectable) medicines?	Yes it does support patient safety.
4. Do you have any suggestions for questions to be included in the Board's FAQ for pharmacists on the compounding of medicines, to support pharmacists in their understanding and application of this guidance?	Nil suggestions at present.
5. Do you have any suggestions on how the proposed guidance could be improved (e.g. any content that should be changed, added or deleted), while still being in accordance with the public interest?	Rather than using the USP guidelines, perhaps more comprehensive guidelines could be developed for Australia. The limitation of current guidelines is that they are too brief and not sufficiently descriptive, whereas TGA guidance which makes reference to PIC/S is too rigorous for patient specific manufacturing.
6. Do you have any other comments on the proposed guidance?	Nil

Please provide your feedback as a Word document (or equivalent) to pharmacyconsultation@ahpra.gov.au by close of business on Wednesday 30 March 2016.